William Blair Has Bullish Forecast for uniQure Q3 Earnings

uniQure N.V. (NASDAQ:QURE) – Investment analysts at William Blair raised their Q3 2026 EPS estimates for uniQure in a report issued on Wednesday, September 24th. William Blair analyst S. Corwin now anticipates that the biotechnology company will post earnings of ($0.29) per share for the quarter, up from their previous forecast of ($0.55). The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure’s Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($1.71) EPS.

Several other research firms have also recently weighed in on QURE. Chardan Capital lifted their price objective on uniQure from $35.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. Cantor Fitzgerald raised their target price on uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. UBS Group set a $95.00 price target on uniQure in a research note on Thursday, September 25th. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of uniQure in a research report on Wednesday, September 24th. Finally, Stifel Nicolaus boosted their target price on shares of uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, uniQure presently has a consensus rating of “Buy” and a consensus price target of $67.17.

uniQure Price Performance

Shares of NASDAQ QURE opened at $58.37 on Monday. uniQure has a 1 year low of $4.45 and a 1 year high of $60.70. The stock has a market capitalization of $3.20 billion, a P/E ratio of -14.89 and a beta of 0.14. The company’s 50-day moving average is $19.22 and its 200 day moving average is $15.53. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The business had revenue of $5.26 million during the quarter, compared to analyst estimates of $5.00 million.

Insider Buying and Selling at uniQure

In other news, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the completion of the transaction, the chief financial officer owned 217,730 shares of the company’s stock, valued at $11,975,150. The trade was a 6.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 226,316 shares of the company’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the completion of the transaction, the chief executive officer owned 651,454 shares in the company, valued at approximately $27,009,282.84. The trade was a 25.78% decrease in their position. The disclosure for this sale can be found here. Insiders sold 244,316 shares of company stock worth $10,328,181 over the last three months. Corporate insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in QURE. Tower Research Capital LLC TRC grew its holdings in shares of uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in uniQure during the 2nd quarter valued at $117,000. Mraz Amerine & Associates Inc. bought a new stake in shares of uniQure in the 1st quarter worth $106,000. Teacher Retirement System of Texas purchased a new position in shares of uniQure in the second quarter worth $151,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of uniQure in the first quarter worth $152,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.